Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease
<p>Abstract</p> <p>Glycoprotein IIb/IIIa inhibitors represent a new promising class of antiplatelet medications. Their use in acute coronary syndromes and for patients undergoing percutaneous coronary intervention has been the subject of a number of large controlled trials using both the intravenous...
Збережено в:
| Автори: | , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
BMC
2001-07-01
|
| Серія: | Current Controlled Trials in Cardiovascular Medicine |
| Предмети: | |
| Онлайн доступ: | http://cvm.controlled-trials.com/content/2/4/171 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|
